Abstract
Mucopolysaccharidoses (MPS) are inherited metabolic disorders, caused by mutations leading to dysfunction of one of enzymes involved in degradation of glycosaminoglycans (GAGs) in lysosomes. Due to their impaired degradation, GAGs accumulate in cells of patients, which results in dysfunction of tissues and organs, including the heart, respiratory system, bones, joints and central nervous system. Depending on the kind of deficient enzyme, 11 types and subtypes of MPS are currently recognized. Although enzyme replacement therapy has been developed for 3 types of MPS (types I, II and VI), this treatment was found to be effective only in management of somatic symptoms. Since all MPS types except IVA, IVB and VI are characterized by various problems with functioning of the central nervous system (CNS), a search for effective treatment of this system is highly desirable. Recent discoveries suggested that substrate reduction therapy may be an efficient method for treatment of MPS patients, including their CNS. In this review, different variants of this therapy will be discussed in the light of recently published reports.
Keywords: mucopolysaccharidoses, lysosomal storage diseases, substrate reduction therapy, gene expression-targeted isoflavone therapy, siRNA, shRNA, glycosaminoglycans (GAGs), large biomolecules, central nervous system (CNS), neurodegenerative diseases, genetic disorders, symptomatic treatment of patients, Sanfilippo disease, hematopoietic stem cells', untreated animals, cognitive functions
Current Pharmaceutical Biotechnology
Title: Substrate Reduction Therapies for Mucopolysaccharidoses
Volume: 12 Issue: 11
Author(s): Joanna Jakobkiewicz-Banecka, Ewa Piotrowska, Magdalena Gabig-Ciminska, Elzbieta Borysiewicz, Monika Slominska-Wojewodzka, Magdalena Narajczyk, Alicja Wegrzyn and Grzegorz Wegrzyn
Affiliation:
Keywords: mucopolysaccharidoses, lysosomal storage diseases, substrate reduction therapy, gene expression-targeted isoflavone therapy, siRNA, shRNA, glycosaminoglycans (GAGs), large biomolecules, central nervous system (CNS), neurodegenerative diseases, genetic disorders, symptomatic treatment of patients, Sanfilippo disease, hematopoietic stem cells', untreated animals, cognitive functions
Abstract: Mucopolysaccharidoses (MPS) are inherited metabolic disorders, caused by mutations leading to dysfunction of one of enzymes involved in degradation of glycosaminoglycans (GAGs) in lysosomes. Due to their impaired degradation, GAGs accumulate in cells of patients, which results in dysfunction of tissues and organs, including the heart, respiratory system, bones, joints and central nervous system. Depending on the kind of deficient enzyme, 11 types and subtypes of MPS are currently recognized. Although enzyme replacement therapy has been developed for 3 types of MPS (types I, II and VI), this treatment was found to be effective only in management of somatic symptoms. Since all MPS types except IVA, IVB and VI are characterized by various problems with functioning of the central nervous system (CNS), a search for effective treatment of this system is highly desirable. Recent discoveries suggested that substrate reduction therapy may be an efficient method for treatment of MPS patients, including their CNS. In this review, different variants of this therapy will be discussed in the light of recently published reports.
Export Options
About this article
Cite this article as:
Jakobkiewicz-Banecka Joanna, Piotrowska Ewa, Gabig-Ciminska Magdalena, Borysiewicz Elzbieta, Slominska-Wojewodzka Monika, Narajczyk Magdalena, Wegrzyn Alicja and Wegrzyn Grzegorz, Substrate Reduction Therapies for Mucopolysaccharidoses, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376932
DOI https://dx.doi.org/10.2174/138920111798376932 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer and Treatment Modalities
Current Cancer Therapy Reviews Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry The Effects of Psychological Stress on Depression
Current Neuropharmacology New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature
Current Pharmaceutical Design Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomarkers NBS1 Heterozygosity and Cancer Risk
Current Genomics Oxidative Stress in Patients with COPD
Current Drug Targets The Fallacy of the Longevity Elixir: Negligible Senescence May be Achieved, but Not by Using Something Physical
Current Aging Science Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Development of Novel Lyophilized Mixed Micelle Amphotericin B Formulation for Treatment of Systemic Fungal Infection
Current Drug Delivery Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Current Guidelines for the Use of Fluoride in Pediatric Dentistry, A Review
Applied Clinical Research, Clinical Trials and Regulatory Affairs Passive Immunization as Tool to Identify Protective HIV-1 Env Epitopes
Current HIV Research Glycans and Glycan-Binding Proteins in Brain: Galectin-1-Induced Expression of Neurotrophic Factors in Astrocytes
Current Drug Targets